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a b s t r a c t 
The COVID-19 outbreak is now one of the most critical crises 
to manage for most of the national healthcare systems in the 
world. In the absence of authorised pharmacological treat- 
ments, many antiretrovirals, including darunavir/cobicistat 
fixed combination, are used off-label in the hospital wards 
as life-treating medicines for COVID-19 patients. Unfortu- 
nately, for most of them, the drug products available on 
the market are not designed to be administered by a naso- 
gastric tube to inpatients of intensive care units. Therefore, 
their manipulation, even if it can strongly affect the prod- 
uct quality, is necessary for the preparation of suspension 
to meet patients’ need. In this situation, it is urgent to pro- 
vide data and guidance to support hospital pharmacists and 
clinicians in their activity. The data in this article indicate 
that darunavir/cobicistat suspensions compounded by phar- 
macists using as active ingredient a commercially available 
tablet can be stable at least for one week. 
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rpecifications table 
Subject Pharmacology, Toxicology and Pharmaceutical Science 
Specific subject area Pharmaceutical Science 
Type of data Table, Figure, Text 
How data were acquired High pressure liquid chromatography (HPLC) 
Data format Raw and analysed 
Parameters for data collection Data on darunavir/cobicistat stability in suspension through one week from 
the preparation after storage at 4 ° and room temperature (RT) 
Description of data collection The drug suspension was prepared in a hospital pharmacy by manipulating the 
darunavir/cobicistat tablet. The drug stability in two-vehicle suspensions was 
tested at different storage conditions (4 °C, RT) for one week. The samples at 
different time points were analysed by HPLC. 
Data source location Turin, Italy 
Data accessibility Analysed data with the article. 
Raw data and chromatogram with supplementary materials. 
alue of the data 
• The data provide evidence on the darunavir/cobicistat chemical stability when they are sus-
pended in different vehicles and stored for one week at different conditions. 
• The data can be useful to healthcare professionals that are trying to fight against the COVID-
19 outbreak. 
• These data can support further clinical studies focused on investigating the effectiveness of
darunavir/cobicistat against COVID-19, especially when the commercially available drug prod-
uct has to be manipulated to meet clinical needs. 
• The data are insights for further studies focused on the development of new dosage forms
indicated for inpatients of intensive care units. 
. Data description 
One of the possible pharmacological treatment of COVID-19 patients resides in the admin-
stration of antiretroviral medicines [1] . The situation is complicated by the absence of ad hoc
uthorised pharmacological therapies. Many antivirals, including darunavir and cobicistat, are
sed off-label in the hospital wards as life-treating medicines for COVID-19 patients. Unfortu-
ately, their manipulation is sometimes necessary because they are not always formulated to be
dministered to non-cooperative patients, like those in intensive care units. Thus, the activity of
ospital pharmacists for the compounding of extemporaneous suspensions by manipulation of
uthorized medicinal products is crucial to provide such life-treating treatments to the hospital
ards [2] . However, the manipulation of medicines can alter their quality profile with potential
mpact on the efficacy and safety of the pharmacological treatment. Therefore, such compound-
ng activities must be guided by the provisions of the Good Compounding Practice and by other
vailable technical guidelines to assure the required quality and the stability of the preparation
ver time [3] . 
For example, the darunavir/cobicistat fixed combination was authorised in the EU as film-
oated tablets (i.e. Rezolsta R ©), which cannot be administered to inpatients by using a naso-
astric tube. The compounding activity of pharmacists consists of the grinding of the dosage
orms and the preparation of a stable suspension. Herein, the chemical stability data of darunavir
nd cobicistat suspended in two different vehicles, namely a commercially available base vehicle
Syrspend R ©) and a 1% w/v carboxymethyl cellulose (CMC) aqueous suspension, is presented. 
Tables 1 and 2 reported the data on both drug assay obtained storing extemporaneous sus-
ensions of the powder obtained by the manipulation of the fixed drug combination at 4 °C and
oom temperature (RT). 
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Table 1 
Data on the chemical stability of darunavir and cobicistat in Syrspend R ©-based extemporaneous suspension when stored 
through one week at 4 °C or at room temperature (RT; ≈25 °C) expressed as mean percentage and relative standard 
deviation (RSD%). 
Storage condition Sampling times (days) Drug assay (%) RSD (%) 
Darunavir Cobicistat Darunavir Cobicistat 
at 
4 °C 
0 100.0 100.0 7.4% 7.0% 
3 120.2 121.8 12.5% 7.8% 
7 120.4 120.0 8.5% 8.2% 
at 
RT 
0 100.0 100.0 7.4% 7.0% 
3 112.5 111.4 17.9% 9.0% 
7 104.3 104.6 1.9% 2.1% 
Table 2 
Data on the chemical stability of darunavir and cobicistat in CMC-based extemporaneous suspension when stored 
through one week at 4 °C or RT ( ≈25 °C) expressed as mean percentage and relative standard deviation (RSD%). 
Storage condition Sampling times (days) Drug assay (%) RSD (%) 
Darunavir Cobicistat Darunavir Cobicistat 
at 
4 °C 
0 100.0 100.0 1.9% 2.5% 
3 93.4 92.8 11.4% 4.2% 
7 105.4 91.1 22.4% 2.4% 
at 
RT. 
0 100.0 100.0 1.9% 2.5% 
3 115.6 113.7 3.6% 2.8% 
7 123.0 106.4 13.3% 7.3% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The high-variability of data obtained by Syrspend R ©-based extemporaneous suspension can
be justified since its sampling resulted more complex than CMC one due to the higher viscosity.
Nevertheless, the data show that both drugs remained within ± 20% of the initial value. Such
data are a proof-of-concept that both drug substances are chemically stable in the suspension
over one week, regardless of the vehicle and the storage condition. 
2. Experimental design, materials, and methods 
2.1. Materials 
Rezolsta R © 800 mg/150 mg film-coated tablets (Janssen-Cilag International NV, I). Tablet core :
hypromellose, colloidal silicon dioxide, silicified microcrystalline cellulose, crospovidone, magne- 
sium stearate. Tablet film-coat : polyvinyl alcohol–partially hydrolysed, macrogol 3350, titanium
dioxide, talc, iron oxide red, iron oxide black [4] . 
Sodium carboxymethyl cellulose (CMC), trisodium citrate dihydrate, and citric acid were
purchased by Farmalabor (I). Syrspend R © was purchased by Fagron Italia. All other chemi-
cals/solvents used in the study were either analytical grade and used without further purifi-
cation. 
2.2. Suspension preparation 
Two tablets of Rezolsta R © were crushed in a mortar to obtain a fine and homogenous powder.
Then, the powder was precisely weighed and loaded in a 50-ml syringe. Using a female-female
Luer-lock connector, the syringe was linked to another one containing 20-mL of the suspension
vehicle. Syrspend R © and 1% w/v CMC solution in pH 4.2 citrate buffer were used as vehicles. The
vehicle volume was set up to obtain a final suspension containing 20 mg/ml of darunavir and
3.75 mg/ml of cobicistat. Moving the syringe plungers, the powder and the solution had mixed
each other to reach a homogenous whitish suspension (appx. 50 syringe complete movements). 
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Table 3 
Chromatographic condition (Gradient). 
Time (min) Solvent A% Solvent B% Flow (mL/min) 
0.0 70 30 1 
5.0 61 39 1 
7.0 56 44 1 
10.0 54 46 1 
11.0 51 49 1 
13.0 48 52 1 
15.5 47 53 1 
18.0 47 53 1 
19.8 46 54 1 
19.9 41 59 1 
20.0 30 70 1 
23.9 30 70 1 
24.0 70 30 1 
28.0 70 30 1 
2
 
A  
n  
t  
w  
t  
a
2
 
a  
t  
p  
(  
U  
s  
b  
a  
D  
d  
v
 
s  
t  
a  
t
C
 
t  .3. Stability studies 
Aliquots of the suspensions (1.5 mL each) were stored at both 4 °C and RT for one week.
t fixed sampling times (0, 3, 7 days), the aliquots of each suspension were heated to RT, if
ecessary, and mixed by a vortex. The samples were diluted 1:1 with a mixture of acetoni-
rile/water (40/60 % v/v), mixed by vortex and, then, sonicated until a homogeneous suspension
as obtained. The sample was split into three replicates diluted 1:125 with a mixture of ace-
onitrile/water (40/60 % v/v). The obtained dilutions were sonicated and mixed by mechanical
gitator for 30 min before being analysed in HPLC. 
.4. HPLC method 
The method was developed and validated modifying a previous published method for plasma
nalyses [5] . The analysis was carried out with a liquid chromatographer Waters 2695 HPLC sys-
em (Milan, Italy) coupled with a 2998 PDA detector. HPLC-PDA system was controlled by Em-
ower 2 Pro-software (version year 2005; Waters). A chromatographic column Luna 5 μm C18
150 ×4.6 mm; Phenomenex, US), protected by a C18 security guard (4.0 ×3.0 mm; Phenomenex,
S) was used for chromatographic separation. The temperature Control Module II (Waters) was
et at 45 °C. The run was performed at 1 mL/min and the temperature was set at 45 °C; the mo-
ile phase was composed of solvent A (KH 2 PO 4 50 mM with orthophosphoric acid, pH = 3.23)
nd solvent B (acetonitrile). The selected wavelength to quantify each drug was: 267 nm for
arunavir and 241 nm for Cobicistat. The runtime was 28 min. Chromatographic Condition (Gra-
ient) were set as shown in Table 3 . Chromatograms of placebo and drug-loaded suspension
ehicles were reported in Supplementary materials. 
Preliminary, stress tests were performed on aliquots of the obtained extemporaneous suspen-
ions to identify degradation patterns of both drugs. Aliquots of both suspensions were stored in
he following conditions: at 96 °C, at RT and 96 °C after the addition of phosphoric acid pH 2.5,
t RT and 96 °C after the addition of ammonia pH 10. Chromatograms of the observed degrada-
ion products during stress tests were included in Supplementary materials. 
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 Supplementary materials 
Supplementary material associated with this article can be found, in the online version, at
doi: 10.1016/j.dib.2020.105552 . 
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